On Tuesday, Vertex Pharmaceuticals hit an important performance benchmark, with its Relative Strength (RS) Rating moving into the 80-plus percentile with an upgrade to 81, a rise from 73 the day before. Keep in mind it hit a roadblock as it tried to break through a pivot point.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
While the stock is not near a proper buy zone right now, having failed to clear from a recent cup without handle base. See if it manages to form and break out of a new proper base. See earnings notes below.
Earnings Update
The company reported 14% earnings growth last quarter, while sales growth came in at 18%. The next quarterly numbers are expected on or around Feb. 7 (today!).
The company earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
